Results 1 to 10 of about 1,770,322 (195)

The tumor therapy landscape of synthetic lethality

Nature Communications, 2021
Various methods have been proposed to identify synthetic lethality interactions, but selective treatment opportunities for various tumors have not yet been explored. Here, the authors develop the Synthetic Lethality Knowledge Graph webserver (SLKG, http:/
Biyu Zhang, Chen Tang, Yanli Yao, Xiaohan Chen, Chi Zhou, Zhiting Wei, Feiyang Xing, Lan Chen, Xiang Cai, Zhiyuan Zhang, Shuyang Sun, Qi Liu   +11 more
doaj   +2 more sources

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Cell, 2021
Precision oncology has made significant advances, mainly by targeting actionable mutations in cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun to explore the utility of tumor transcriptome to guide patient ...
Joo Sang Lee, Nishanth Ulhas Nair, Hongui Cha   +2 more
exaly   +2 more sources

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

Acta Pharmaceutica Sinica B, 2021
Synthetic lethality is a proven effective antitumor strategy that has attracted great attention. Large-scale screening has revealed many synthetic lethal genetic phenotypes, and relevant small-molecule drugs have also been implemented in clinical ...
Kailin Li, Jieqiong You, Qian Wu, Wen Meng, Qiaojun He, Bo Yang, Chengliang Zhu, Ji Cao   +7 more
doaj   +3 more sources

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Journal of Hematology & Oncology, 2020
Synthetic lethality is a lethal phenomenon in which the occurrence of a single genetic event is tolerable for cell survival, whereas the co-occurrence of multiple genetic events results in cell death. The main obstacle for synthetic lethality lies in the
Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen, Xiujun Cai   +10 more
doaj   +2 more sources

Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics [PDF]

Journal of Integrative Bioinformatics, 2017
The development of improved cancer therapies is frequently cited as an urgent unmet medical need. Here we describe how genetic interactions are being therapeutically exploited to identify novel targeted treatments for cancer.
Benstead-Hume Graeme, Wooller Sarah K., Pearl Frances M.G.   +2 more
doaj   +3 more sources

Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age

Trends in Pharmacological Sciences, 2021
Deregulation of MYC is among the most frequent oncogenic drivers of cancer. Developing targeted therapies against MYC is, therefore, one of the most critical unmet needs of cancer therapy.
Dexter Kai Hao Thng, Tan Boon Toh, Edward Kai-Hua Chow   +2 more
exaly   +2 more sources

Comprehensive interrogation of synthetic lethality in the DNA damage response. [PDF]

Nature
The DNA damage response (DDR) is a multifaceted network of pathways that preserves genome stability1,2. Unravelling the complementary interplay between these pathways remains a challenge3,4.
Fielden J, Siegner SM, Gallagher DN, Schröder MS, Dello Stritto MR, Lam S, Kobel L, Schlapansky MF, Jackson SP, Cejka P, Jost M, Corn JE.   +11 more
europepmc   +2 more sources

The power and the promise of synthetic lethality for clinical application in cancer treatment

Biomedicine and Pharmacotherapy
Synthetic lethality is a phenomenon wherein the simultaneous deficiency of two or more genes results in cell death, while the deficiency of any individual gene does not lead to cell death. In recent years, synthetic lethality has emerged as a significant
Da Fu, Ji-Bin Liu
exaly   +2 more sources

Synthetic lethality of mRNA quality control complexes in cancer. [PDF]

Nature
Synthetic lethality exploits the genetic vulnerabilities of cancer cells to enable a targeted, precision approach to treat cancer1. Over the past 15 years, synthetic lethal cancer target discovery approaches have led to clinical successes of PARP ...
Prindle V, Richardson AE, Sher KR, Kongpachith S, Kentala K, Petiwala S, Cheng D, Widomski D, Le P, Torrent M, Chen A, Walker S, Palczewski MB, Mitra D, Manaves V, Shi X, Lu C, Sandoval S, Dezso Z, Buchanan FG, Verduzco D, Bierie B, Meulbroek JA, Pappano WN, Plotnik JP.   +24 more
europepmc   +2 more sources

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

Cell Reports, 2016
ATR and CHK1 maintain cancer cell survival under replication stress and inhibitors of both kinases are currently undergoing clinical trials. As ATR activity is increased after CHK1 inhibition, we hypothesized that this may indicate an increased reliance ...
Kumar Sanjiv, Anna Hagenkort, José Manuel Calderón-Montaño, Tobias Koolmeister, Philip M. Reaper, Oliver Mortusewicz, Sylvain A. Jacques, Raoul V. Kuiper, Niklas Schultz, Martin Scobie, Peter A. Charlton, John R. Pollard, Ulrika Warpman Berglund, Mikael Altun, Thomas Helleday   +14 more
doaj   +3 more sources